Looks like you clickedhttps://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Abiraterone-acetate-plus-prednisone-and-LHRH-therapy-versus-abiraterone-acetate-plus-prednisone-while-sparing-LHRH-therapy-in-patients-with-progressive-metastatic-and-chemotherapy-naive-castration-resistant-prostate-cancer-results-from-the-SPARE-trial
If you do not want to visit that page, you can close this browser tab.
